Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • CORRESPONDENCE

Peru to punish bending of clinical-trial rules

Peru’s National Institute of Health (INS) is urgently reviewing its procedures for authorization and supervision of clinical trials for COVID-19 treatments and vaccines, after protocol deviations in one such trial (see Nature 592, 174–175 (2021) and C. F. Cáceres et al. Nature 592, 685; 2021). Now under investigation by a regulatory body, the incident dented public confidence in the integrity of our scientific community.

The INS aims to ensure that such irregularities can never happen again. It plans to create a National Bioethics Commission, to establish a sanctions procedure and to upgrade training in ethics and scientific integrity for researchers.

There are currently 28 other clinical trials related to COVID-19 (4 vaccines and 24 treatments) in progress in Peru. All conform to international ethical and scientific standards.

Nature 595, 650 (2021)

doi: https://doi.org/10.1038/d41586-021-02056-x

Competing Interests

The authors declare no competing interests.

Subjects

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing

Search

Quick links